Transcatheter Solutions for Tricuspid Valve Disease

News Release

FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates, Inc., +1 508-359-4005, x108

4Tech appoints Paul Cornelison as Global Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs

"Paul brings nearly 25 years of experience in Medical Devices, with specific knowledge and achievements in transcatheter solutions for Mitral valve disease. I am personally delighted that Paul has chosen to join 4Tech to further solidify our position as the leader in transcatheter solutions to treat Tricuspid valve disease."
Carine Schorochoff, CEO, 4Tech Inc.

GALWAY, Ireland, April 7, 2016—**4Tech Inc.**, which is developing the world's first transcatheter device, **TriCinch™**, for repair of the Tricuspid heart valve, today announced that it has appointed **Paul Cornelison**, as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs.

Most recently, Paul was Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs at **CardiAQ Valve Technologies** Inc., a developer of Transcatheter Mitral Valve Replacement (recently acquired by Edwards Lifesciences). Previously Paul served as Vice President of Regulatory Affairs & Quality Assurance at Cardiac Dimensions, Inc., one of the earliest percutaneous mitral valve repair companies. Earlier in his career, he held regulatory and quality assurance positions at Arrow International (now part of Teleflex Medical), RCRI, Inc., St. Jude Medical (Daig Division), Angeion Corporation, Telectronics Pacing Systems, Aequitron Medical and Lake Region Manufacturing. He holds a master's degree in Engineering (Management of Technology) from the University of Pennsylvania, and bachelors of arts degrees in Management and Spanish from St. Johns' University (MN).

"Paul offers a broad range of quality, regulatory and clinical experience from nearly 25 years in the medical device industry, and has been a pioneer in the field of transcatheter valve therapies," said **Carine Schorochoff,** Co-Founder and CEO of 4Tech. "As we finalize our second-generation 4Tech TriCinch system and prepare to start definitive clinical trials, I cannot think of anyone more qualified to pave the way for the European approval of the first transcatheter tricuspid repair technology."

Recent News Releases:
March 16, 2016—4Tech appoints Hardip Thakerar as Global Vice President of Therapy Development
March 9, 2016—4Tech Completes $29 Million Series B Round of Financing

About 4Tech Inc.
4Tech Inc. (www.4techtricuspid.com) is incorporated in Delaware, USA, with operations in Galway, Ireland (4Tech Cardio Ltd). 4Tech has developed a proprietary transcatheter solution for the treatment of TR. Because of its unique anchoring and tensioning mechanism, the 4Tech TriCinch™ System for Transcatheter Tricuspid Valve Repair allows a simple and reproducible percutaneous procedure, designed to reduce TR

and restore patient quality of life, while also allowing substantial potential cost-savings for the healthcare systems.

Caution: The 4Tech TriCinch™ System for Transcatheter Tricuspid Valve Repair is in the early phase of development. It will not be available in the USA for clinical trials until further notice and is NOT available for sale.

Caution: This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of 4Tech are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA's approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.

# # #